VX-840
/ Vertex
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 08, 2022
A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=88 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Completed
Trial completion • Nephrology • Renal Disease
1 to 1
Of
1
Go to page
1